NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved the repurchase of up to $120 million of its common stock.
 
"Given the underlying strength of Illumina's business and the recent turbulence in the equity markets, we think our current stock price is undervalued,” said Illumina President and CEO Jay Flatley. “Therefore, we believe the stock buy-back program is in the best interests of our stockholders.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.